Castle Biosciences (CSTL) Other Non-Current Assets (2018 - 2026)

Castle Biosciences has reported Other Non-Current Assets for 9 years, with the latest figure at $4.4 million in Q2 2026.

• Quarterly Other Non-Current Assets rose 257.94% year-over-year to $4.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.4 million (up 257.94% YoY) and the FY2025 annual result came in at $3.8 million, up 206.92% from the prior year.
• Other Non-Current Assets climbed to $4.4 million in Q2 2026 per CSTL's latest filing, from $4.3 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $4.4 million in Q2 2026 and troughed at $792000.0 in Q1 2023.
• A 5-year average of $1.9 million and a median of $1.4 million in 2023 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2026: Other Non-Current Assets slumped 70.66% in 2023, then soared 257.94% in 2026.
• Over 5 years, Other Non-Current Assets stood at $1.1 million in 2022, then increased by 29.73% to $1.4 million in 2023, then retreated by 14.72% to $1.2 million in 2024, then jumped by 206.92% to $3.8 million in 2025, then increased by 17.86% to $4.4 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $4.4 million, $4.3 million, and $3.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.